A Phase 1 interventional study of Sudapyridine 30mg and Sudapyridine 100mg SAD in Healthy, sponsored by Shanghai Jiatan Pharmatech Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-07.
Sponsored by Shanghai Jiatan Pharmatech Co., Ltd · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this study is to evaluate the safety, tolerability as well as pharmacokinetics of Sudapyridine (WX-081) in Chinese volunteers.
In this study, a single-center, randomized, double-blind, placebo-controlled, dose-ascending design was used to evaluate the safety, tolerability and pharmacokinetic characteristics of Sudapyridine (WX-081) tablets in healthy Chinese subjects using placebo as control.
This study was divided into two stages. The first stage evaluated the tolerance of single administration, pharmacokinetic characteristics, and the effect of food on PK. The second stage evaluated the tolerance of multiple administration and PK characteristics.
Shanghai Jiatan Pharmatech Co., Ltd is the lead sponsor of 11 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received Sudapyridine 30 mg single dose orally.
Drug: Sudapyridine 30mg
Participants received Sudapyridine 100 mg single dose orally.
Drug: Sudapyridine 100mg SAD
Participants received Sudapyridine 200 mg single dose orally.
Drug: Sudapyridine 200mg SAD
Participants received Sudapyridine 200 mg orally for multiple doses.
Drug: Sudapyridine 200mg MAD
Participants received Sudapyridine 300 mg orally for multiple doses.
Drug: Sudapyridine 300mg MAD
Participants received Placebo 100 mg single dose orally.
Other: Placebo tablet SAD
Participants received Placebo 200 mg single dose orally.
Other: Placebo 200mg SAD
articipants received Placebo 200 mg orally for multiple doses.
Other: Placebo tablet MAD
Participants received Placebo 300 mg orally for multiple doses.
Other: Placebo tablet MAD
Sudapyridine capsule 30mg, orally, single dose
Also known as: Sudapyridine capsule 30mg SAD
Sudapyridine tablet, 100mg orally, single dose
Also known as: Sudapyridine tablet 100mg SAD
Sudapyridine tablet, 200mg orally, single dose
Also known as: Sudapyridine tablet 200mg SAD
Sudapyridine tablet, 200mg orally once a day for 14 days
Also known as: Sudapyridine tablet 200mg MAD
Sudapyridine tablet, 300mg orally once a day for 14 days
Also known as: Sudapyridine tablet 300mg MAD
Placebo tablet, 100mg orally, single dose
Also known as: Placebo tablet 100mg
Placebo tablet, 200mg orally, single dose
Placebo tablet, 200mg orally once a day for 14 days
Also known as: Placebo tablet 200mg MAD
Placebo tablet, 300mg orally once a day for 14 days
Also known as: Placebo tablet 300mg MAD
Maximum plasma concentration (Cmax) of Sudapyridine
PK parameter
Time frame: 0,1,2,3,4,6,8,12,24,48,72,96,120,144 hours post-dose
Time to reach plasma Cmax (Tmax) of Sudapyridine
PK parameter
Time frame: 0,1,2,3,4,6,8,12,24,48,72,96,120,144 hours post-dose
Area under the plasma concentration-time curve (AUC) of Sudapyridine
PK parameter
Time frame: 0,1,2,3,4,6,8,12,24,48,72,96,120,144 hours post-dose
Terminal elimination half-life (t½) of Sudapyridine
PK parameter
Time frame: 0,1,2,3,4,6,8,12,24,48,72,96,120,144 hours post-dose
Volume of distribution (Vd/F) of Sudapyridine
PK parameter
Time frame: 0,1,2,3,4,6,8,12,24,48,72,96,120,144 hours post-dose
Apparent clearance (CL/F) of Sudapyridine
PK parameter
Time frame: 0,1,2,3,4,6,8,12,24,48,72,96,120,144 hours post-dose
Elimination rate constant Ke of Sudapyridine
PK parameter
Time frame: 0,1,2,3,4,6,8,12,24,48,72,96,120,144 hours post-dose
Number of participants with adverse events (AEs) or Serious Adverse Events (SAEs)
safety parameter
Time frame: 0,1,2,3,4,6,8,12,24,48,72,96,120,144 hours post-dose
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2019 to primary completion in Jul 2020, 16 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sudapyridine
Shanghai Jiatan Pharmatech Co., Ltd